Skip to main content
. Author manuscript; available in PMC: 2019 Nov 1.
Published in final edited form as: Epidemiology. 2018 Nov;29(6):895–903. doi: 10.1097/EDE.0000000000000907

Table 2.

Distribution of covariates by exposure

Baseline Covariates DPP4 inhibitor Sulfonylurea
n = 25,849 n = 88,312
Mean (SD) Mean (SD)
Age 56 (11.0) 54 (12.6)
Count (%) Count (%)
Gender (F) 12,185 (47.1) 40,510 (45.9)
Chronic Kidney Disease 1,419 (5.5) 4,053 (4.6)
Hypoglycemia 757 (2.9) 2,435 (2.8)
Diabetic Nephropathy 935 (3.6) 2,300 (2.6)
Diabetic Neuropathy 1,594 (6.2) 4,401 (5.0)
Diabetic Retinopathy 1,025 (4.0) 2,726 (3.1)
Diabetic Peripheral Circulatory Disorder 510 (2.0) 1,497 (1.7)
Erectile Dysfunction 689 (2.7) 2,098 (2.4)
Skin Infections 341 (1.3) 1,199 (1.4)
Diabetic Unspecified Complications 842 (3.3) 2,514 (2.8)
Alphaglucosidase 104 (0.4) 198 (0.2)
Glitazones 8,188 (31.7) 16,184 (18.3)
GLP1RA 1,326 (5.1) 3,097 (3.5)
Insulin 2,844 (11.0) 6,079 (6.9)
Meglitinides 945 (3.7) 934 (1.1)
Metformin 13,662 (52.9) 47,816 (54.1)
Mean (SD) Mean (SD)
Number of ambulatory visits 8.5 9.1 7.8 9.4
Number of emergency department visits 0.2 1.5 0.2 1.5
Number of inpatient visits 0.1 0.4 0.2 0.5
Number of institutional stays 0.1 0.8 0.1 1.1
Number of outpatient visits 0.4 1.7 0.4 1.8
Number of classes of medication 7.4 4.5 6.5 4.2
Number of generic medications 8.4 4.8 7.4 4.5
Number of dispensations 20.1 15.6 15.6 14.0

Age defined at the index date, all other characteristics defined using data within the 183 days prior to the index date. SD indicates standard deviation.